The Influence of Serotoninergic Drugs on Dopaminergic Neurotransmission in Rat Substantia Nigra, Striatum and Limbic Forebrain in Vivo

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1992 Jul 1

PMID 1328893

Citations 6

Authors

H Nissbrandt

N Waters

S Hjorth

Affiliations

Soon will be listed here.

Abstract

The effects of serotoninergic drugs on dopaminergic neurotransmission in the substantia nigra, the striatum and the limbic forebrain of rat have been investigated. The accumulation of 3-methoxytyramine (3-MT) following inhibition of monoamine oxidase with pargyline was used as an indirect measure of dopamine (DA) activity in vivo. The effects of the following serotoninergic drugs were tested: the 5-HT1A receptor agonist 8-OH-DPAT, the 5-HT1B receptor agonist trifluoromethyl-phenylpiperazine (TFMPP), CGS 12066 B and RU 24969, the 5-HT1A/1B antagonist (+/-)pindolol, the 5-HT2/1C receptor antagonist ritanserin, the 5-HT2/1C receptor agonist DL-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), the 5-HT3 receptor antagonist BRL 43694, the unselective 5-HT receptor antagonist methiothepin, and carbidopa + L-5-hydroxytryptophan (L-5-HTP) to achieve a general, unselective stimulation of multiple 5-HT receptors. In the substantia nigra, carbidopa + 5-HTP treatment increased the 3-MT accumulation by 26% and decreased the DA concentration to 67% of controls, tentatively suggesting a 5-HTP-induced displacement of nigral DA. A minor, non dose-related reduction in nigral 3-MT was seen after the 5-HT1A receptor agonist 8-OH-DPAT. None of the other serotonin receptor acting drugs induced any pronounced effect on the nigral 3-MT accumulation. Taken together, the findings provide little support for the idea that one single 5-HT receptor subtype serves a modulatory function on DA activity in the substantia nigra. In the striatum and the limbic forebrain, trifluoromethyl-phenylpiperazine dose-dependently increased the 3-MT accumulation to maximally 200%-220% of controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: a single-dose study.

Lee H, Wang G, Curley L, Sollers J, Kydd R, Kirk I Psychopharmacology (Berl). 2015; 233(5):863-71.

PMID: 26630992 DOI: 10.1007/s00213-015-4165-x.

Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.

Curley L, Kydd R, Robertson M, Pillai A, McNair N, Lee H Psychopharmacology (Berl). 2015; 232(16):2969-80.

PMID: 25893641 DOI: 10.1007/s00213-015-3933-y.

Determining the subjective and physiological effects of BZP combined with TFMPP in human males.

Lin J, Jan R, Lee H, Jensen M, Kydd R, Russell B Psychopharmacology (Berl). 2010; 214(3):761-8.

PMID: 21060995 DOI: 10.1007/s00213-010-2081-7.

Effects of trifluoromethylphenylpiperazine (TFMPP) on interhemispheric communication.

Lee H, Kydd R, Lim V, Kirk I, Russell B Psychopharmacology (Berl). 2010; 213(4):707-14.

PMID: 20924753 DOI: 10.1007/s00213-010-2025-2.

Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata.

Threlfell S, Cragg S, Kallo I, Turi G, Coen C, Greenfield S J Neurosci. 2004; 24(40):8704-10.

PMID: 15470136 PMC: 6729965. DOI: 10.1523/JNEUROSCI.2690-04.2004.

References

Markwell M, Haas S, Bieber L, Tolbert N . A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978; 87(1):206-10. DOI: 10.1016/0003-2697(78)90586-9. View

Schmidt C, Taylor V, Abbate G, Nieduzak T . 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. J Pharmacol Exp Ther. 1991; 256(1):230-5. View

Leysen J, Gommeren W, Van Gompel P, Wynants J, Janssen P, Laduron P . Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol. 1985; 27(6):600-11. View

Schoeffter P, Hoyer D . Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?. Naunyn Schmiedebergs Arch Pharmacol. 1989; 339(6):675-83. DOI: 10.1007/BF00168661. View

Felice L, Felice J, Kissinger P . Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography. J Neurochem. 1978; 31(6):1461-5. DOI: 10.1111/j.1471-4159.1978.tb06573.x. View

Carlsson A, Lindqvist M . Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol. 1973; 25(6):437-40. DOI: 10.1111/j.2042-7158.1973.tb09129.x. View

Santiago M, Westerink B . Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. J Neurochem. 1991; 57(3):738-47. DOI: 10.1111/j.1471-4159.1991.tb08214.x. View

ANDEN N, Grabowska M, Strombom U . Different alpha-adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents. Naunyn Schmiedebergs Arch Pharmacol. 1976; 292(1):43-52. DOI: 10.1007/BF00506488. View

van der Kooy D, Hattori T . Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labeling study in the rat. Brain Res. 1980; 186(1):1-7. DOI: 10.1016/0006-8993(80)90250-4. View

10.

Dray A, Davies J, Oakley N, Tongroach P, Vellucci S . The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res. 1978; 151(3):431-42. DOI: 10.1016/0006-8993(78)91077-6. View

11.

Pettibone D, Williams M . Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol. 1984; 33(9):1531-5. DOI: 10.1016/0006-2952(84)90424-6. View

12.

Hoyer D, Middlemiss D . Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol Sci. 1989; 10(4):130-2. DOI: 10.1016/0165-6147(89)90159-4. View

13.

Soubrie P, Reisine T, Glowinski J . Functional aspects of serotonin transmission in the basal ganglia: a review and an in vivo approach using the push-pull cannula technique. Neuroscience. 1984; 13(3):605-25. DOI: 10.1016/0306-4522(84)90082-4. View

14.

Neale R, Fallon S, Boyar W, Wasley J, Martin L, Stone G . Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur J Pharmacol. 1987; 136(1):1-9. DOI: 10.1016/0014-2999(87)90772-2. View

15.

Robertson G, Damsma G, Fibiger H . Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J Neurosci. 1991; 11(7):2209-16. PMC: 6575457. View

16.

Anden N, Grabowska M . Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. Eur J Pharmacol. 1976; 39(2):275-82. DOI: 10.1016/0014-2999(76)90136-9. View

17.

Titeler M, Lyon R, Glennon R . Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl). 1988; 94(2):213-6. DOI: 10.1007/BF00176847. View

18.

Hoyer D . Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res. 1988; 8(1-4):59-81. DOI: 10.3109/10799898809048978. View

19.

KEHR W . 3-Methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1976; 293(3):209-15. DOI: 10.1007/BF00507343. View

20.

Asarch K, Ransom R, Shih J . 5-HT-1a and 5-HT-1b selectivity of two phenylpiperazine derivatives: evidence for 5-HT-1b heterogeneity. Life Sci. 1985; 36(13):1265-73. DOI: 10.1016/0024-3205(85)90271-1. View